Bacterial infections in cirrhosis: Epidemiological changes with invasive procedures and norfloxacin prophylaxis

By Javier Fernández, M. Navasa, Juliá Gómez, J. Colmenero, J. Vila, V. Arroyo, J. Rodés. Hepatology, 2002

986 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology, Surgery

View Paper: https://www.semanticscholar.org/paper/394c03f1960924608f4df54d2de93460a7365b0d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. P. Ginés
2. M. Bernardi
3. W. Laleman
4. P. Angeli
5. J. Trebicka
6. G. Garcia‐Tsao
7. Aleksander Krag
8. A. Sanyal

In Hepatology

1. P. Ginés
2. M. Bernardi
3. P. Angeli
4. W. Laleman
5. J. Trebicka
6. Rajeshwar P. Mookerjee
7. G. Garcia‐Tsao
8. Aleksander Krag

In Surgery

1. P. Ginés

Citations in the corpus

• Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. (2014, background): “Patients with cirrhosis and IBO more frequently have SBP than patients without bacterial overgrowth [31].”
• Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: A prospective study (2012, methodology): “The empirical antibiotic regimen used in this series was as follows: (1) intravenous (IV) ceftriaxone for SBP, SE, SB, UTI, and sepsis of unknown origin; (2) IV ceftriaxone plus cloxacillin or amoxicillin/clavulanic acid for cellulitis; (3) IV ceftriaxone and a macrolide or levofloxacin (plus clinda”
• EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. (2018, background): “SBP is very common in patients with cirrhosis and ascites [241,242].”